APA (7th ed.) Citation

YN, L., FW, D., TQ, L., Y, L., L, X., GB, S., . . . HQ, Y. (2026). FPSIR predicts clinical therapeutic responses and survival outcomes in patients with metastatic colorectal cancer undergoing first-line bevacizumab-containing chemotherapy. Frontiers in immunology, 17, 1683928. https://doi.org/10.3389/fimmu.2026.1683928

Chicago Style (17th ed.) Citation

YN, Li, Deng FW, Lan TQ, Lu Y, Xiang L, Song GB, Peng T, Cheng XX, and Ying HQ. "FPSIR Predicts Clinical Therapeutic Responses and Survival Outcomes in Patients with Metastatic Colorectal Cancer Undergoing First-line Bevacizumab-containing Chemotherapy." Frontiers in Immunology 17 (2026): 1683928. https://doi.org/10.3389/fimmu.2026.1683928.

MLA (9th ed.) Citation

YN, Li, et al. "FPSIR Predicts Clinical Therapeutic Responses and Survival Outcomes in Patients with Metastatic Colorectal Cancer Undergoing First-line Bevacizumab-containing Chemotherapy." Frontiers in Immunology, vol. 17, 2026, p. 1683928, https://doi.org/10.3389/fimmu.2026.1683928.